Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T Cell Therapy for CMV Infection After Stem Cell Transplant
NCT02982902Phase 1Recruiting
- Start
- May 2020
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in cytomegalovirus infection (CMV). Primary endpoint: Incidence of adverse events at 100 days. Started May 2020; status: recruiting.
02
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02982902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982902.